Ouro Medicines

Gilead Sciences Gains an Opportunity for Immune System Reset With $1.7B Ouro Acquisition

Gilead Sciences is acquiring Ouro Medicines, a startup developing T cell engagers for a range of autoimmune diseases. Separately, Gilead is negotiating a deal with Galapagos to share in the development and potential commercialization of the Ouro drug.

By Frank Vinluan

BioPharma, Pharma

Immunology Startup Ouro Sets Out With $120M for Drugs That Reset the Immune System

Ouro Medicines’ drugs deplete disease-driving immune cells, allowing the immune system to reset with naïve cells that don’t attack the body. Monograph Capital founded the startup in partnership with GSK.

By Frank Vinluan